Inhibition Of Ovarian Tumor Growth With Reconbinant Soluble VEGFR-2 Adenovirus

Objective: The growth and persistence of solid tumors and their metastasis are angiogenesis-dependent. Targeting angiogenesis represents a new strategy for the development of antitumor therapies. VEGFR-2 (KDR/Flk-1) is the major VEGF functional receptor. Soluble VEGFR-2 is the extracellular Ig-like domains of VEGFR-2. In this study, we designed the antiangiogenic gene therapy with reconbinant soluble Flk-1 adenovirus, to explore its effect on inhibition of tumor growth , and also explore its antitumor effect in combination with DDP.Materials and Methods:The animal model was established in 6-8 weeks nude mice with SKOV3 cell. And then 10 days later, nude mice were treated with ad-sFlk-1 (reconbinant soluble Flk-1 adenovirus) 1×10~9 pfu/100μlPBS/mouse, or empty vector 1×10~9 pfu/100μlPBS/mouse or PBS 100μl/mouse by trail vein and repeated 14 days later; or were treated with DDP 200μg/100μlPBS/mouse by intraperitoneal every 7 days, twice for all .Then we observed the volume of tumor, the side effects of therapy, as well asmade immunohistochemical analysis of tumor tissues. Results: Our data demonstrated the treatment with ad-sFlk-1 significantly inhibited tumor growth (PO.05), inhibited angiogenesis in tumor tissues by immunohistochemical analysis (CD31 staining) (P<0.05), and increased apoptotic cells in the tumor tissues (TUNEL) (P<0.05). Furthmore, the combination therapy with ad-sFlk-1 and DDP increased the therapeutic efficacy.Conclusion: The present findings proved the combination therapy with solube VEGFR-2 and DDP is an efficient antitumor strategy, which may be of importance for the further exploration.